Caspofungin Treatment Guidelines

Introduction to Caspofungin Therapy

• The American College of Clinical Pharmacology recommends that caspofungin does not require dose adjustment in patients with renal impairment, including those with acute renal failure 1

Dosage Adjustments and Considerations

• The Infectious Diseases Society of America suggests that for patients with moderate hepatic impairment (Child-Pugh 7-9), the maintenance dose of caspofungin should be reduced to 35 mg daily in adults 1

Treatment Duration and Indications

• The Clinical Infectious Diseases guidelines recommend that treatment for candidemia and invasive candidiasis should continue for at least 14 days after the last positive blood culture and until clinical symptoms are resolved and neutropenia has improved 2

Drug Interactions and Precautions

• The Praxis Medical Insights guideline notes that caspofungin reduces the AUC of tacrolimus by approximately 20%, requiring monitoring of tacrolimus levels 1
• The Clinical Infectious Diseases journal reports that cyclosporine increases the AUC of caspofungin by approximately 35%, necessitating cautious use due to transient elevations in liver enzymes 1

Antifungal Activity and Spectrum

• The Clinical Infectious Diseases guidelines state that caspofungin has potent activity against Candida albicans and C. glabrata, but higher MICs against C. parapsilosis 3, 4
• The Praxis Medical Insights guideline suggests that for C. parapsilosis infections, fluconazole or lipid-formulated amphotericin B may be preferred, although continuing caspofungin is reasonable if the patient is clinically stable 1